{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:24:00Z","timestamp":1792891440308,"version":"4.5.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41375-026-03067-1","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:27:28Z","timestamp":1785216448000},"page":"1868-1878","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Blastic plasmacytoid dendritic cell neoplasm: ontogeny, immunophenotype, genetics and epigenetics, immune dysregulation, skin tropism and therapeutic implications"],"prefix":"10.1038","volume":"40","author":[{"given":"Changqing","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-1601","authenticated-orcid":false,"given":"Dinesh","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6821-4556","authenticated-orcid":false,"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8079-9945","authenticated-orcid":false,"given":"Zhenya","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2621-3584","authenticated-orcid":false,"given":"Joseph D.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"3067_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1182\/hematology.2024000553","volume":"2024","author":"N Pemmaraju","year":"2024","unstructured":"Pemmaraju N. BPDCN: state of the art. Hematol Am Soc Hematol Educ Program. 2024;2024:279\u201386.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"3067_CR2","doi-asserted-by":"crossref","unstructured":"Yin CC, Pemmaraju N, You MJ, Li S, Xu J, Wang W, et al. Integrated clinical genotype-phenotype characteristics of blastic plasmacytoid dendritic cell neoplasm. Cancers (Basel). 2021;13:5888.","DOI":"10.3390\/cancers13235888"},{"key":"3067_CR3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/bmt.2012.242","volume":"48","author":"M Unteregger","year":"2013","unstructured":"Unteregger M, Valentin A, Zinke-Cerwenka W, Troppan K, Deutsch A, Cerroni L, et al. Unrelated SCT induces long-term remission in patients with blastic plasmacytoid dendritic cell neoplasm. Bone Marrow Transpl. 2013;48:799\u2013802.","journal-title":"Bone Marrow Transpl"},{"key":"3067_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/modpathol.2015.145","volume":"29","author":"F Facchetti","year":"2016","unstructured":"Facchetti F, Cigognetti M, Fisogni S, Rossi G, Lonardi S, Vermi W. Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol. 2016;29:98\u2013111.","journal-title":"Mod Pathol"},{"key":"3067_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.hoc.2020.01.001","volume":"34","author":"JP Hirner","year":"2020","unstructured":"Hirner JP, O\u2019Malley JT, LeBoeuf NR. Blastic plasmacytoid dendritic cell neoplasm. Dermatol Perspect Hematol Oncol Clin North Am. 2020;34:501\u20139.","journal-title":"Dermatol Perspect Hematol Oncol Clin North Am"},{"key":"3067_CR6","doi-asserted-by":"crossref","unstructured":"Mehra S, Taylor J. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review of the disease, central nervous system presentations, and treatment strategies. Cells. 2024;13:243.","DOI":"10.3390\/cells13030243"},{"key":"3067_CR7","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1182\/blood.2021011817","volume":"138","author":"N Pemmaraju","year":"2021","unstructured":"Pemmaraju N, Wilson NR, Khoury JD, Jain N, Daver N, Pierce S, et al. Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood. 2021;138:1373\u20137.","journal-title":"Blood"},{"key":"3067_CR8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/ajh.27737","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Luskin MR, Gangat N, LeBoeuf NR, Feraco AM, Lane AA. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): 2025 update on diagnosis, pathophysiology, risk assessment, and management. Am J Hematol. 2025;100:1408\u201322.","journal-title":"Am J Hematol"},{"key":"3067_CR9","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/s41375-023-01968-z","volume":"37","author":"B Cuglievan","year":"2023","unstructured":"Cuglievan B, Connors J, He J, Khazal S, Yedururi S, Dai J, et al. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia. 2023;37:1767\u201378.","journal-title":"Leukemia"},{"key":"3067_CR10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/blood.2022017865","volume":"141","author":"N Pemmaraju","year":"2023","unstructured":"Pemmaraju N, Kantarjian H, Sweet K, Wang E, Senapati J, Wilson NR, et al. North american blastic plasmacytoid dendritic cell neoplasm consortium: position on standards of care and areas of need. Blood. 2023;141:567\u201378.","journal-title":"Blood"},{"key":"3067_CR11","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nri2358","volume":"8","author":"M Gilliet","year":"2008","unstructured":"Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol. 2008;8:594\u2013606.","journal-title":"Nat Rev Immunol"},{"key":"3067_CR12","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"3067_CR13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.6004\/jnccn.2023.7026","volume":"21","author":"A Jain","year":"2023","unstructured":"Jain A, Sweet K. Blastic plasmacytoid dendritic cell neoplasm. J Natl Compr Canc Netw. 2023;21:515\u201321.","journal-title":"J Natl Compr Canc Netw"},{"key":"3067_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41590-018-0136-9","volume":"19","author":"PF Rodrigues","year":"2018","unstructured":"Rodrigues PF, Alberti-Servera L, Eremin A, Grajales-Reyes GE, Ivanek R, Tussiwand R. Distinct progenitor lineages contribute to the heterogeneity of plasmacytoid dendritic cells. Nat Immunol. 2018;19:711\u201322.","journal-title":"Nat Immunol"},{"key":"3067_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.immuni.2018.12.027","volume":"50","author":"B Reizis","year":"2019","unstructured":"Reizis B. Plasmacytoid dendritic cells: development, regulation, and function. Immunity. 2019;50:37\u201350.","journal-title":"Immunity"},{"key":"3067_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2008.09.016","volume":"135","author":"B Cisse","year":"2008","unstructured":"Cisse B, Caton ML, Lehner M, Maeda T, Scheu S, Locksley R, et al. Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development. Cell. 2008;135:37\u201348.","journal-title":"Cell"},{"key":"3067_CR17","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ccell.2016.10.002","volume":"30","author":"M Ceribelli","year":"2016","unstructured":"Ceribelli M, Hou ZE, Kelly PN, Huang DW, Wright G, Ganapathi K, et al. A Druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell. 2016;30:764\u201378.","journal-title":"Cancer Cell"},{"key":"3067_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11899-018-0489-z","volume":"13","author":"JD Khoury","year":"2018","unstructured":"Khoury JD. Blastic plasmacytoid dendritic cell neoplasm. Curr Hematol Malig Rep. 2018;13:477\u201383.","journal-title":"Curr Hematol Malig Rep"},{"key":"3067_CR19","doi-asserted-by":"publisher","first-page":"E998","DOI":"10.1073\/pnas.1319228111","volume":"111","author":"GC Ippolito","year":"2014","unstructured":"Ippolito GC, Dekker JD, Wang YH, Lee BK, Shaffer AL 3rd, et al. Dendritic cell fate is determined by BCL11A. Proc Natl Acad Sci USA. 2014;111:E998\u20131006.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3067_CR20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.immuni.2016.08.013","volume":"45","author":"D Sichien","year":"2016","unstructured":"Sichien D, Scott CL, Martens L, Vanderkerken M, Van Gassen S, Plantinga M, et al. IRF8 transcription factor controls survival and function of terminally differentiated conventional and plasmacytoid dendritic cells, respectively. Immunity. 2016;45:626\u201340.","journal-title":"Immunity"},{"key":"3067_CR21","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1084\/jem.20041231","volume":"200","author":"R Schotte","year":"2004","unstructured":"Schotte R, Nagasawa M, Weijer K, Spits H, Blom B. The ETS transcription factor Spi-B is required for human plasmacytoid dendritic cell development. J Exp Med. 2004;200:1503\u20139.","journal-title":"J Exp Med"},{"key":"3067_CR22","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1084\/jem.20130443","volume":"210","author":"CM Sawai","year":"2013","unstructured":"Sawai CM, Sisirak V, Ghosh HS, Hou EZ, Ceribelli M, Staudt LM, et al. Transcription factor Runx2 controls the development and migration of plasmacytoid dendritic cells. J Exp Med. 2013;210:2151\u20139.","journal-title":"J Exp Med"},{"key":"3067_CR23","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1182\/blood-2016-02-698118","volume":"128","author":"K Onodera","year":"2016","unstructured":"Onodera K, Fujiwara T, Onishi Y, Itoh-Nakadai A, Okitsu Y, Fukuhara N, et al. GATA2 regulates dendritic cell differentiation. Blood. 2016;128:508\u201318.","journal-title":"Blood"},{"key":"3067_CR24","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/s41375-022-01538-9","volume":"36","author":"M Khanlari","year":"2022","unstructured":"Khanlari M, Yin CC, Takahashi K, Lachowiez C, Tang G, Loghavi S, et al. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia. 2022;36:1343\u201350.","journal-title":"Leukemia"},{"key":"3067_CR25","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1182\/bloodadvances.2020003359","volume":"5","author":"F Renosi","year":"2021","unstructured":"Renosi F, Roggy A, Giguelay A, Soret L, Viailly PJ, Cheok M, et al. Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. Blood Adv. 2021;5:1540\u201351.","journal-title":"Blood Adv"},{"key":"3067_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100352","volume":"37","author":"S Sadigh","year":"2024","unstructured":"Sadigh S, DeAngelo DJ, Garcia JS, Hasserjian RP, Hergott CB, Lane AA, et al. Cutaneous manifestations of myeloid neoplasms exhibit broad and divergent morphologic and immunophenotypic features but share ancestral clonal mutations with bone marrow. Mod Pathol. 2024;37:100352.","journal-title":"Mod Pathol"},{"key":"3067_CR27","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1038\/s41375-021-01228-y","volume":"35","author":"K Batta","year":"2021","unstructured":"Batta K, Bossenbroek HM, Pemmaraju N, Wilks DP, Chasty R, Dennis M, et al. Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. Leukemia. 2021;35:3299\u2013303.","journal-title":"Leukemia"},{"key":"3067_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00893-9","volume":"13","author":"T Yamada","year":"2023","unstructured":"Yamada T, Hiramoto N, Mori T, Yamashita D, Tai Y, Yamamoto R, et al. Coincidence of cutaneous blastic plasmacytoid dendritic cell neoplasm and myelodysplastic syndrome derived from clonal hematopoiesis. Blood Cancer J. 2023;13:119.","journal-title":"Blood Cancer J"},{"key":"3067_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1656157","volume":"16","author":"Y Sun","year":"2025","unstructured":"Sun Y, Liu Y, Liu N, Zhang X, Huang W, Hu L. Blastic plasmacytoid dendritic cell neoplasm secondary to acute myeloid leukemia with shared mutations in TET2 and DNMT3A: a case report and literature review. Front Immunol. 2025;16:1656157.","journal-title":"Front Immunol"},{"key":"3067_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00699-1","volume":"12","author":"A Kunstner","year":"2022","unstructured":"Kunstner A, Schwarting J, Witte HM, Bernard V, Stolting S, Kusch K, et al. Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm. Blood Cancer J. 2022;12:101.","journal-title":"Blood Cancer J"},{"key":"3067_CR31","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/ajh.23567","volume":"88","author":"K Alayed","year":"2013","unstructured":"Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88:1055\u201361.","journal-title":"Am J Hematol"},{"key":"3067_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.immuni.2020.07.003","volume":"53","author":"U Cytlak","year":"2020","unstructured":"Cytlak U, Resteu A, Pagan S, Green K, Milne P, Maisuria S, et al. Differential IRF8 Transcription Factor Requirement Defines Two Pathways of Dendritic Cell Development in Humans. Immunity. 2020;53:353\u201370 e358.","journal-title":"Immunity"},{"key":"3067_CR33","doi-asserted-by":"crossref","unstructured":"Lubin R, Patel AA, Mackerodt J, Zhang Y, Gvili R, Mulder K, et al. The lifespan and kinetics of human dendritic cell subsets and their precursors in health and inflammation. J Exp Med. 2024;221:e20220867.","DOI":"10.1084\/jem.20220867"},{"key":"3067_CR34","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1182\/bloodadvances.2020002474","volume":"4","author":"K Laribi","year":"2020","unstructured":"Laribi K, Baugier de Materre A, Sobh M, Cerroni L, Valentini CG, Aoki T, et al. Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. Blood Adv. 2020;4:4838\u201348.","journal-title":"Blood Adv"},{"key":"3067_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/PAS.0b013e3181c5e26b","volume":"34","author":"C Cota","year":"2010","unstructured":"Cota C, Vale E, Viana I, Requena L, Ferrara G, Anemona L, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol. 2010;34:75\u201387.","journal-title":"Am J Surg Pathol"},{"key":"3067_CR36","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1038\/s41375-018-0154-5","volume":"32","author":"K Sakamoto","year":"2018","unstructured":"Sakamoto K, Katayama R, Asaka R, Sakata S, Baba S, Nakasone H, et al. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. Leukemia. 2018;32:2590\u2013603.","journal-title":"Leukemia"},{"key":"3067_CR37","doi-asserted-by":"crossref","unstructured":"El Hussein S, Wang W. Flow cytometry profiling of plasmacytoid dendritic cell neoplasms. Cancers (Basel). 2024:162118.","DOI":"10.3390\/cancers16112118"},{"key":"3067_CR38","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"3067_CR39","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3324\/haematol.2020.247569","volume":"106","author":"W Wang","year":"2021","unstructured":"Wang W, Khoury JD, Miranda RN, Jorgensen JL, Xu J, Loghavi S, et al. Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2021;106:1047\u201355.","journal-title":"Haematologica"},{"key":"3067_CR40","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/cyto.b.20469","volume":"76","author":"EZ Reineks","year":"2009","unstructured":"Reineks EZ, Osei ES, Rosenberg A, Auletta J, Meyerson HJ. CD22 expression on blastic plasmacytoid dendritic cell neoplasms and reactivity of anti-CD22 antibodies to peripheral blood dendritic cells. Cytom B Clin Cytom. 2009;76:237\u201348.","journal-title":"Cytom B Clin Cytom"},{"key":"3067_CR41","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/PAS.0000000000000156","volume":"38","author":"F Julia","year":"2014","unstructured":"Julia F, Dalle S, Duru G, Balme B, Vergier B, Ortonne N, et al. Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol. 2014;38:673\u201380.","journal-title":"Am J Surg Pathol"},{"key":"3067_CR42","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","volume":"7","author":"J Montero","year":"2017","unstructured":"Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discov. 2017;7:156\u201364.","journal-title":"Cancer Discov"},{"key":"3067_CR43","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1002\/cncr.34345","volume":"128","author":"IJ Adimora","year":"2022","unstructured":"Adimora IJ, Wilson NR, Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a promising future in the era of targeted therapeutics. Cancer. 2022;128:3019\u201326.","journal-title":"Cancer"},{"key":"3067_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107479","volume":"139","author":"X Hu","year":"2024","unstructured":"Hu X, Ediriwickrema A, Saleem A, Tan B, Pemmaraju N, Mannis GN. CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123. Leuk Res. 2024;139:107479.","journal-title":"Leuk Res"},{"key":"3067_CR45","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1097\/PAS.0000000000001316","volume":"43","author":"N Sukswai","year":"2019","unstructured":"Sukswai N, Aung PP, Yin CC, Li S, Wang W, Wang SA, et al. Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm. Am J Surg Pathol. 2019;43:1429\u201337.","journal-title":"Am J Surg Pathol"},{"key":"3067_CR46","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.1182\/blood-2008-06-162651","volume":"112","author":"B Malleret","year":"2008","unstructured":"Malleret B, Maneglier B, Karlsson I, Lebon P, Nascimbeni M, Perie L, et al. Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood. 2008;112:4598\u2013608.","journal-title":"Blood"},{"key":"3067_CR47","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/PAP.0b013e3181bb6bc2","volume":"16","author":"AG Jegalian","year":"2009","unstructured":"Jegalian AG, Facchetti F, Jaffe ES. Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol. 2009;16:392\u2013404.","journal-title":"Adv Anat Pathol"},{"key":"3067_CR48","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1084\/jem.20132620","volume":"211","author":"SL Rowland","year":"2014","unstructured":"Rowland SL, Riggs JM, Gilfillan S, Bugatti M, Vermi W, Kolbeck R, et al. Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model. J Exp Med. 2014;211:1977\u201391.","journal-title":"J Exp Med"},{"key":"3067_CR49","doi-asserted-by":"crossref","unstructured":"Wang W, Xu J, Khoury JD, Pemmaraju N, Fang H, Miranda RN, et al. Immunophenotypic and molecular features of acute myeloid leukemia with plasmacytoid dendritic cell differentiation are distinct from blastic plasmacytoid dendritic cell neoplasm. Cancers (Basel). 2022;14:3375.","DOI":"10.3390\/cancers14143375"},{"key":"3067_CR50","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/ajcp\/aqac174","volume":"159","author":"SJ Wu","year":"2023","unstructured":"Wu SJ, Sadigh S, Lane AA, Pinkus GS. Expanding the immunophenotypic spectrum of neoplastic and reactive plasmacytoid dendritic cells. Am J Clin Pathol. 2023;159:455\u201363.","journal-title":"Am J Clin Pathol"},{"key":"3067_CR51","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.2023021786","volume":"144","author":"L de Leval","year":"2024","unstructured":"de Leval L, Gaulard P, Dogan A. A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas. Blood. 2024;144:1855\u201372.","journal-title":"Blood"},{"key":"3067_CR52","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s43018-025-00986-3","volume":"6","author":"K Aliazis","year":"2025","unstructured":"Aliazis K, Christofides A, Shah R, Yeo YY, Jiang S, Charest A, et al. The tumor microenvironment\u2019s role in the response to immune checkpoint blockade. Nat Cancer. 2025;6:924\u201337.","journal-title":"Nat Cancer"},{"key":"3067_CR53","doi-asserted-by":"crossref","unstructured":"Alvarez Flores MB, Sopena Corvinos M, Guillen Santos R, Cava Valenciano F. High-sensitivity flow cytometry for the reliable detection of measurable residual disease in hematological malignancies in clinical laboratories. Diseases. 2024;12:338.","DOI":"10.3390\/diseases12120338"},{"key":"3067_CR54","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/jha2.617","volume":"4","author":"X Zhang","year":"2023","unstructured":"Zhang X, Hsi ED, Crane GM, Cheng YW. Biallelic TET2 mutations and canonical ASXL1 mutations are frequent and cooccur in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): an institutional experience and review of literature. EJHaem. 2023;4:236\u201340.","journal-title":"EJHaem"},{"key":"3067_CR55","doi-asserted-by":"publisher","first-page":"495","DOI":"10.18632\/oncotarget.28742","volume":"16","author":"F Fei","year":"2025","unstructured":"Fei F, Telatar M, Tomasian V, Chang L, Danilova O, Arias-Stella J, et al. Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience. Oncotarget. 2025;16:495\u2013507.","journal-title":"Oncotarget"},{"key":"3067_CR56","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1182\/bloodadvances.2022007879","volume":"7","author":"H Beird","year":"2023","unstructured":"Beird H, Yin CC, Khoury JD, Pierce S, Abbas HA, Zhao L, et al. TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2023;7:2000\u20133.","journal-title":"Blood Adv"},{"key":"3067_CR57","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","volume":"20","author":"K Moran-Crusio","year":"2011","unstructured":"Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20:11\u201324.","journal-title":"Cancer Cell"},{"key":"3067_CR58","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","volume":"20","author":"C Quivoron","year":"2011","unstructured":"Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20:25\u201338.","journal-title":"Cancer Cell"},{"key":"3067_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57614-y","volume":"16","author":"Y Yang","year":"2025","unstructured":"Yang Y, Cathelin S, Liu ACH, Subedi A, Maher A, Hosseini M, et al. TET2 deficiency increases the competitive advantage of hematopoietic stem and progenitor cells through upregulation of thrombopoietin receptor signaling. Nat Commun. 2025;16:2384.","journal-title":"Nat Commun"},{"key":"3067_CR60","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","volume":"22","author":"O Abdel-Wahab","year":"2012","unstructured":"Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 2012;22:180\u201393.","journal-title":"Cancer Cell"},{"key":"3067_CR61","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/ng.1009","volume":"44","author":"GA Challen","year":"2011","unstructured":"Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2011;44:23\u201331.","journal-title":"Nat Genet"},{"key":"3067_CR62","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12185-017-2257-6","volume":"106","author":"H Kunimoto","year":"2017","unstructured":"Kunimoto H, Nakajima H. Epigenetic dysregulation of hematopoietic stem cells and preleukemic state. Int J Hematol. 2017;106:34\u201344.","journal-title":"Int J Hematol"},{"key":"3067_CR63","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fonc.2016.00187","volume":"6","author":"H Sato","year":"2016","unstructured":"Sato H, Wheat JC, Steidl U, Ito K. DNMT3A and TET2 in the pre-leukemic phase of hematopoietic disorders. Front Oncol. 2016;6:187.","journal-title":"Front Oncol"},{"key":"3067_CR64","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-20-1513","volume":"12","author":"K Togami","year":"2022","unstructured":"Togami K, Chung SS, Madan V, Booth CAG, Kenyon CM, Cabal-Hierro L, et al. Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis. Cancer Discov. 2022;12:522\u201341.","journal-title":"Cancer Discov"},{"key":"3067_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7042","volume":"6","author":"V Madan","year":"2015","unstructured":"Madan V, Kanojia D, Li J, Okamoto R, Sato-Otsubo A, Kohlmann A, et al. Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. Nat Commun. 2015;6:6042.","journal-title":"Nat Commun"},{"key":"3067_CR66","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/nar\/gkad1180","volume":"52","author":"YS Kwon","year":"2024","unstructured":"Kwon YS, Jin SW, Song H. Global analysis of binding sites of U2AF1 and ZRSR2 reveals RNA elements required for mutually exclusive splicing by the U2- and U12-type spliceosome. Nucleic Acids Res. 2024;52:1420\u201334.","journal-title":"Nucleic Acids Res"},{"key":"3067_CR67","doi-asserted-by":"crossref","unstructured":"Bencze D, Fekete T, Pazmandi K. Type I interferon production of plasmacytoid dendritic cells under control. Int J Mol Sci. 2021;22:4190.","DOI":"10.3390\/ijms22084190"},{"key":"3067_CR68","doi-asserted-by":"crossref","unstructured":"Renosi F, Callanan M, Lefebvre C. Genetics and epigenetics in neoplasms with plasmacytoid dendritic cells. Cancers (Basel). 2022;14:4132.","DOI":"10.3390\/cancers14174132"},{"key":"3067_CR69","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1182\/blood.2024024787","volume":"145","author":"T Zhang","year":"2025","unstructured":"Zhang T, Wang YF, Montoya A, Patrascan I, Nebioglu N, Pallikonda HA, et al. Conserved helical motifs in the IKZF1 disordered region mediate NuRD interaction and transcriptional repression. Blood. 2025;145:422\u201337.","journal-title":"Blood"},{"key":"3067_CR70","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/gcc.22831","volume":"59","author":"AN Bastidas Torres","year":"2020","unstructured":"Bastidas Torres AN, Cats D, Mei H, Fanoni D, Gliozzo J, Corti L, et al. Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm. Genes Chromosomes Cancer. 2020;59:295\u2013308.","journal-title":"Genes Chromosomes Cancer"},{"key":"3067_CR71","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/sj.leu.2403452","volume":"18","author":"N Bendriss-Vermare","year":"2004","unstructured":"Bendriss-Vermare N, Chaperot L, Peoc\u2019h M, Vanbervliet B, Jacob MC, Briere F, et al. In situ leukemic plasmacytoid dendritic cells pattern of chemokine receptors expression and in vitro migratory response. Leukemia. 2004;18:1491\u20138.","journal-title":"Leukemia"},{"key":"3067_CR72","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1182\/blood-2010-07-295626","volume":"118","author":"V Sisirak","year":"2011","unstructured":"Sisirak V, Vey N, Vanbervliet B, Duhen T, Puisieux I, Homey B, et al. CCR6\/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues. Blood. 2011;118:5130\u201340.","journal-title":"Blood"},{"key":"3067_CR73","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.hoc.2020.01.003","volume":"34","author":"K Sakamoto","year":"2020","unstructured":"Sakamoto K, Takeuchi K. Cytogenetics of blastic plasmacytoid dendritic cell neoplasm: cytogenetics of blastic plasmacytoid dendritic cell neoplasm: chromosomal rearrangements and DNA copy-number alterations. Hematol Oncol Clin North Am. 2020;34:523\u201338.","journal-title":"Hematol Oncol Clin North Am"},{"key":"3067_CR74","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1182\/blood.V99.11.4154","volume":"99","author":"D Leroux","year":"2002","unstructured":"Leroux D, Mugneret F, Callanan M, Radford-Weiss I, Dastugue N, Feuillard J, et al. CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Francais de Cytogenetique Hematologique. Blood. 2002;99:4154\u20139.","journal-title":"Blood"},{"key":"3067_CR75","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.leukres.2018.09.006","volume":"73","author":"Z Tang","year":"2018","unstructured":"Tang Z, Li Y, Wang W, Yin CC, Tang G, Aung PP, et al. Genomic aberrations involving 12p\/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. Leuk Res. 2018;73:86\u201394.","journal-title":"Leuk Res"},{"key":"3067_CR76","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13039-016-0232-1","volume":"9","author":"Z Tang","year":"2016","unstructured":"Tang Z, Tang G, Wang SA, Lu X, Young KH, Bueso-Ramos CE, et al. Simultaneous deletion of 3\u2019ETV6 and 5\u2019EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review. Mol Cytogenet. 2016;9:23.","journal-title":"Mol Cytogenet"},{"key":"3067_CR77","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s12185-025-04031-y","volume":"122","author":"R Chiriac","year":"2025","unstructured":"Chiriac R. MYC-rearranged blastic plasmacytoid dendritic cell neoplasm with immunoblastoid features. Int J Hematol. 2025;122:163\u20134.","journal-title":"Int J Hematol"},{"key":"3067_CR78","doi-asserted-by":"crossref","unstructured":"Booth CAG, Bouyssou JM, Togami K, Armand O, Rivas HG, Yan K, et al. BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia. JCI Insight. 2024;9:e183889.","DOI":"10.1172\/jci.insight.183889"},{"key":"3067_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03899-4","volume":"25","author":"R Li","year":"2025","unstructured":"Li R, Kuang W, Yang H, Zhang B, Zhao K, Fang W, et al. Single cell sequencing deciphering the heterogeneous landscape of blastic plasmacytoid dendritic cell neoplasm with novel MYB-ZFAT fusion gene. Cancer Cell Int. 2025;25:274.","journal-title":"Cancer Cell Int"},{"key":"3067_CR80","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.leukres.2011.07.029","volume":"36","author":"T Toya","year":"2012","unstructured":"Toya T, Nishimoto N, Koya J, Nakagawa M, Nakamura F, Kandabashi K, et al. The first case of blastic plasmacytoid dendritic cell neoplasm with MLL-ENL rearrangement. Leuk Res. 2012;36:117\u20138.","journal-title":"Leuk Res"},{"key":"3067_CR81","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.cancergen.2015.04.011","volume":"208","author":"N Yang","year":"2015","unstructured":"Yang N, Huh J, Chung WS, Cho MS, Ryu KH, Chung HS. KMT2A (MLL)-MLLT1 rearrangement in blastic plasmacytoid dendritic cell neoplasm. Cancer Genet. 2015;208:464\u20137.","journal-title":"Cancer Genet"},{"key":"3067_CR82","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41375-024-02240-8","volume":"38","author":"A Kunstner","year":"2024","unstructured":"Kunstner A, Schwarting J, Witte HM, Xing P, Bernard V, Stolting S, et al. Genome-wide DNA methylation-analysis of blastic plasmacytoid dendritic cell neoplasm identifies distinct molecular features. Leukemia. 2024;38:1086\u201398.","journal-title":"Leukemia"},{"key":"3067_CR83","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/sj.leu.2404257","volume":"20","author":"J Roman-Gomez","year":"2006","unstructured":"Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Garate L, et al. Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome. Leukemia. 2006;20:1445\u20138.","journal-title":"Leukemia"},{"key":"3067_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1646","volume":"16","author":"BN Rodriguez","year":"2024","unstructured":"Rodriguez BN, Huang H, Chia JJ, Hoffmann A. The noncanonical NFkappaB pathway: Regulatory mechanisms in health and disease. WIREs Mech Dis. 2024;16:e1646.","journal-title":"WIREs Mech Dis"},{"key":"3067_CR85","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1146\/annurev-immunol-031210-101345","volume":"29","author":"B Reizis","year":"2011","unstructured":"Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V. Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol. 2011;29:163\u201383.","journal-title":"Annu Rev Immunol"},{"key":"3067_CR86","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1097\/PAS.0000000000001747","volume":"45","author":"L Lorenzi","year":"2021","unstructured":"Lorenzi L, Lonardi S, Vairo D, Bernardelli A, Tomaselli M, Bugatti M, et al. E-cadherin expression and blunted interferon response in blastic plasmacytoid dendritic cell neoplasm. Am J Surg Pathol. 2021;45:1428\u201338.","journal-title":"Am J Surg Pathol"},{"key":"3067_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0262-0","volume":"9","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Beird HC, Khan M, Wang F, Alfayez M, Cai T, et al. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood Cancer J. 2019;9:99.","journal-title":"Blood Cancer J"},{"key":"3067_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0262-0","volume":"9","author":"HC Beird","year":"2019","unstructured":"Beird HC, Khan M, Wang F, Alfayez M, Cai T, Zhao L, et al. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood Cancer J. 2019;9:99.","journal-title":"Blood Cancer J"},{"key":"3067_CR89","doi-asserted-by":"crossref","unstructured":"Aung PP, Sukswai N, Nejati R, Loghavi S, Chen W, Torres-Cabala CA, et al. PD1\/PD-L1 expression in blastic plasmacytoid dendritic cell neoplasm. Cancers (Basel). 2019;11:695.","DOI":"10.3390\/cancers11050695"},{"key":"3067_CR90","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227\u201342.","journal-title":"Nat Rev Immunol"},{"key":"3067_CR91","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/j.humpath.2010.04.005","volume":"41","author":"DM Dorfman","year":"2010","unstructured":"Dorfman DM, Hornick JL, Shahsafaei A, Freeman GJ. The phosphatidylserine receptors, T cell immunoglobulin mucin proteins 3 and 4, are markers of histiocytic sarcoma and other histiocytic and dendritic cell neoplasms. Hum Pathol. 2010;41:1486\u201394.","journal-title":"Hum Pathol"},{"key":"3067_CR92","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.4049\/jimmunol.181.8.5219","volume":"181","author":"D Benitez-Ribas","year":"2008","unstructured":"Benitez-Ribas D, Tacken P, Punt CJ, de Vries IJ, Figdor CG. Activation of human plasmacytoid dendritic cells by TLR9 impairs Fc gammaRII-mediated uptake of immune complexes and presentation by MHC class II. J Immunol. 2008;181:5219\u201324.","journal-title":"J Immunol"},{"key":"3067_CR93","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/40166","volume":"389","author":"RC Fuhlbrigge","year":"1997","unstructured":"Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature. 1997;389:978\u201381.","journal-title":"Nature"},{"key":"3067_CR94","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1309\/0QPPAVTUPCV9UCLV","volume":"122","author":"T Petrella","year":"2004","unstructured":"Petrella T, Meijer CJ, Dalac S, Willemze R, Maynadie M, Machet L, et al. TCL1 and CLA expression in agranular CD4\/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am J Clin Pathol. 2004;122:307\u201313.","journal-title":"Am J Clin Pathol"},{"key":"3067_CR95","doi-asserted-by":"crossref","unstructured":"Martinez AL, Shannon MJ, Sloan T, Mace EM. CD56\/NCAM mediates cell migration of human NK cells by promoting integrin-mediated adhesion turnover. bioRxiv. 2023. Nov 22: 1\u201311","DOI":"10.1101\/2023.11.21.567714"},{"key":"3067_CR96","doi-asserted-by":"crossref","unstructured":"Van Acker HH, Van Acker ZP, Versteven M, Ponsaerts P, Pende D, Berneman ZN, et al. CD56 homodimerization and participation in anti-tumor immune effector cell functioning: a role for interleukin-15. Cancers (Basel). 2019;11:1029.","DOI":"10.3390\/cancers11071029"},{"key":"3067_CR97","doi-asserted-by":"publisher","first-page":"10174","DOI":"10.18632\/oncotarget.7101","volume":"7","author":"L Martin-Martin","year":"2016","unstructured":"Martin-Martin L, Almeida J, Pomares H, Gonzalez-Barca E, Bravo P, Gimenez T, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7:10174\u201381.","journal-title":"Oncotarget"},{"key":"3067_CR98","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E23-12-0463","volume":"35","author":"AL Martinez","year":"2024","unstructured":"Martinez AL, Shannon MJ, Sloan T, Mace EM. CD56\/NCAM mediates cell migration of human NK cells by promoting integrin-mediated adhesion turnover. Mol Biol Cell. 2024;35:ar64.","journal-title":"Mol Biol Cell"},{"key":"3067_CR99","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1172\/JCI15994","volume":"111","author":"JP Levesque","year":"2003","unstructured":"Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4\/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest. 2003;111:187\u201396.","journal-title":"J Clin Invest"},{"key":"3067_CR100","doi-asserted-by":"publisher","first-page":"244","DOI":"10.4049\/jimmunol.174.1.244","volume":"174","author":"BA Zabel","year":"2005","unstructured":"Zabel BA, Silverio AM, Butcher EC. Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood. J Immunol. 2005;174:244\u201351.","journal-title":"J Immunol"},{"key":"3067_CR101","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1084\/jem.20080129","volume":"206","author":"C Albanesi","year":"2009","unstructured":"Albanesi C, Scarponi C, Pallotta S, Daniele R, Bosisio D, Madonna S, et al. Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med. 2009;206:249\u201358.","journal-title":"J Exp Med"},{"key":"3067_CR102","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/d41586-024-04068-9","volume":"637","author":"G Guglielmi","year":"2025","unstructured":"Guglielmi G. The skin\u2019s \u2018surprise\u2019 power: it has its very own immune system. Nature. 2025;637:260.","journal-title":"Nature"},{"key":"3067_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1515390","volume":"16","author":"FM Mentucci","year":"2025","unstructured":"Mentucci FM, Ferrara MG, Ercole A, Rumie Vittar NB, Lamberti MJ. Interplay between cancer-associated fibroblasts and dendritic cells: implications for tumor immunity. Front Immunol. 2025;16:1515390.","journal-title":"Front Immunol"},{"key":"3067_CR104","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41586-023-06156-8","volume":"618","author":"GK Griffin","year":"2023","unstructured":"Griffin GK, Booth CAG, Togami K, Chung SS, Ssozi D, Verga JA, et al. Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin. Nature. 2023;618:834\u201341.","journal-title":"Nature"},{"key":"3067_CR105","doi-asserted-by":"publisher","first-page":"24196","DOI":"10.1073\/pnas.1907860116","volume":"116","author":"S Premi","year":"2019","unstructured":"Premi S, Han L, Mehta S, Knight J, Zhao D, Palmatier MA, et al. Genomic sites hypersensitive to ultraviolet radiation. Proc Natl Acad Sci USA. 2019;116:24196\u2013205.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3067_CR106","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3324\/haematol.2010.026179","volume":"95","author":"AG Jegalian","year":"2010","unstructured":"Jegalian AG, Buxbaum NP, Facchetti F, Raffeld M, Pittaluga S, Wayne AS, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010;95:1873\u20139.","journal-title":"Haematologica"},{"key":"3067_CR107","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1038\/leu.2017.101","volume":"31","author":"K Suzuki","year":"2017","unstructured":"Suzuki K, Suzuki Y, Hama A, Muramatsu H, Nakatochi M, Gunji M, et al. Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2017;31:1629\u201333.","journal-title":"Leukemia"},{"key":"3067_CR108","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s12185-020-03070-x","volume":"113","author":"C Liao","year":"2021","unstructured":"Liao C, Hu NX, Song H, Zhang JY, Shen DY, Xu XJ, et al. Pediatric blastic plasmacytoid dendritic cell neoplasm: report of four cases and review of literature. Int J Hematol. 2021;113:751\u20139.","journal-title":"Int J Hematol"},{"key":"3067_CR109","doi-asserted-by":"publisher","first-page":"7084","DOI":"10.1182\/bloodadvances.2023011586","volume":"7","author":"CG Valentini","year":"2023","unstructured":"Valentini CG, Pagano L. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm: a 2-speed cure in the United States and European Union. Blood Adv. 2023;7:7084\u20136.","journal-title":"Blood Adv"},{"key":"3067_CR110","first-page":"44","volume":"109","author":"MR Luskin","year":"2024","unstructured":"Luskin MR, Lane AA. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2024;109:44\u201352.","journal-title":"Haematologica"},{"key":"3067_CR111","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1080\/10428194.2024.2305288","volume":"65","author":"N Pemmaraju","year":"2024","unstructured":"Pemmaraju N, Madanat YF, Rizzieri D, Fazal S, Rampal R, Mannis G, et al. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations. Leuk Lymphoma. 2024;65:548\u201359.","journal-title":"Leuk Lymphoma"},{"key":"3067_CR112","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1080\/17474086.2021.1988848","volume":"14","author":"AJ DiPippo","year":"2021","unstructured":"DiPippo AJ, Wilson NR, Pemmaraju N. Targeting CD123 in BPDCN: an emerging field. Expert Rev Hematol. 2021;14:993\u20131004.","journal-title":"Expert Rev Hematol"},{"key":"3067_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100086","volume":"2","author":"N Pemmaraju","year":"2025","unstructured":"Pemmaraju N, Phan LH, Fell G, Luskin MR, Swaminathan M, Pierce S, et al. Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN. Blood Neoplasia. 2025;2:100086.","journal-title":"Blood Neoplasia"},{"key":"3067_CR114","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1080\/17501911.2025.2557179","volume":"17","author":"J Cheng","year":"2025","unstructured":"Cheng J, O\u2019Connell C. Novel approaches to the use of hypomethylating agents in myeloid malignancies. Epigenomics. 2025;17:1201\u201312.","journal-title":"Epigenomics"},{"key":"3067_CR115","doi-asserted-by":"publisher","first-page":"7007","DOI":"10.1182\/bloodadvances.2023011308","volume":"7","author":"HS Murthy","year":"2023","unstructured":"Murthy HS, Zhang MJ, Chen K, Ahmed S, Deotare U, Ganguly S, et al. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis. Blood Adv. 2023;7:7007\u201316.","journal-title":"Blood Adv"},{"key":"3067_CR116","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41409-021-01478-5","volume":"57","author":"Q Bashir","year":"2022","unstructured":"Bashir Q, Milton DR, Popat UR, Kebriaei P, Hosing C, Khouri IF, et al. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transpl. 2022;57:51\u201356.","journal-title":"Bone Marrow Transpl"},{"key":"3067_CR117","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.clml.2018.07.295","volume":"18","author":"MA Kharfan-Dabaja","year":"2018","unstructured":"Kharfan-Dabaja MA, Reljic T, Murthy HS, Ayala E, Kumar A. Allogeneic hematopoietic cell transplantation is an effective treatment for blastic plasmacytoid dendritic cell neoplasm in first complete remission: systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2018;18:703\u20139 e701.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3067_CR118","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1007\/s00277-025-06493-w","volume":"104","author":"M Herling","year":"2025","unstructured":"Herling M, Angelucci E, Benoit TM, Rivoli G, Curti A, Gotze KS, et al. Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm: real world results from a European Named Patient Program. Ann Hematol. 2025;104:4121\u201331.","journal-title":"Ann Hematol"},{"key":"3067_CR119","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO.22.00034","volume":"40","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, et al. Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol. 2022;40:3032\u20136.","journal-title":"J Clin Oncol"},{"key":"3067_CR120","volume":"16","author":"Y Sasaki","year":"2024","unstructured":"Sasaki Y, Murai S, Shiozawa E, Yamochi T, Hattori N. Blastic plasmacytoid dendritic cell neoplasm in long-term complete remission after venetoclax monotherapy. Cureus. 2024;16:e52446.","journal-title":"Cureus"},{"key":"3067_CR121","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1056\/NEJMc1808354","volume":"379","author":"ME Agha","year":"2018","unstructured":"Agha ME, Monaghan SA, Swerdlow SH. Venetoclax in a patient with a blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2018;379:1479\u201381.","journal-title":"N Engl J Med"},{"key":"3067_CR122","doi-asserted-by":"publisher","first-page":"E62","DOI":"10.1002\/ajh.26417","volume":"97","author":"N Gangat","year":"2022","unstructured":"Gangat N, Konopleva M, Patnaik MM, Jabbour E, DiNardo C, Al-Kali A, et al. Venetoclax and hypomethylating agents in older\/unfit patients with blastic plasmacytoid dendritic cell neoplasm. Am J Hematol. 2022;97:E62\u2013E67.","journal-title":"Am J Hematol"},{"key":"3067_CR123","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1182\/blood-2025-653","volume":"146","author":"ALM Lane","year":"2025","unstructured":"Lane ALM, Keating J, Leboeuf N, Garcia J, Shimony S, Leonard R, et al. Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial. Blood. 2025;146:653.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03067-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03067-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03067-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:02:22Z","timestamp":1787684542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03067-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":123,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3067"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03067-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}